Abbott Labs (ABT) Reaches Settlements in Litigation Related to Direct Purchaser Class Action; to Pay $184M
More News related to ABT
- Absolute Customers Speak Out About Recent Laptop Theft Experiences
- Halo Pharmaceutical, Inc. Acquires Whippany Manufacturing Facility from Abbott
- Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
- Absolute Showcases LoJack for Laptops at MacWorld Expo and CES
- Celera (CRA) and Abbott (ABT) Revise Strategic Alliance
More News related to Corporate News
- Standard & Poor's Lowers Ratings on PNC Financial (PNC)
- DA Davidson Downgrades Cascade (CAE) to Underperform
- BMO Downgrades F5 Networks (FFIV) to Market Perform
- Sterne Agee Downgrades EZCorp (EZPW) to Neutral
- CL King Downgrades Steven Madden (SHOO) to Neutral
In a Form 8-K, Abbott Laboratories (NYSE: ABT) has reached settlements in the litigation pending in the United States District Court for the District of Delaware involving direct purchaser class action claims and claims brought by certain individual plaintiffs related to the sale of fenofibrate formulations.
Under the settlements, Abbott will pay approximately $184 million to resolve these claims. Settlement agreements have also been reached resolving some of the other previously disclosed fenofibrate litigation. The amounts in those settlements are not material. Abbott intends to treat the settlement payments as a specified item in Q408.
Abbott Laboratories engages in the development, manufacture, and sale of health care products worldwide.
Related Categories
Corporate NewsStocks Mentioned
-0.28Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
